TNF-α LYTAC (Draupnir)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameTNF-α LYTAC (Draupnir)
Drug Alias NameN/A
ClassificationBiologics > Lysosome-Targeting Chimaeras (LYTAC)
Mechanisms of ActionTumor necrosis factor α degraders
TargetsTumor necrosis factor α
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEU
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDraupnir Bio APS
China Registration ClassN/A

Develop Information

Active CompaniesDraupnir Bio APS
Inactive CompaniesN/A
Active IndicationsInflammation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A